Abstract 250P
Background
Adjuvant treatment for patients (pts) with endometrial cancer (EC) is decided based on risk assessment of recurrence and distant metastasis. Carcinomas of non-endometrioid (NE) histologies are rare, classified as high-risk and adjuvant treatment is recommended.
Methods
Retrospective analysis of EC pts diagnosed and treated in two units during 10 years (2009-2018) with a focus on pts with NEEC. After surgery and multidisciplinary discussion, pts had either no further treatment, radiotherapy (RT), chemotherapy (CT) followed by RT or CT. We compared these approaches using survival analysis.
Results
From a total of 330 pts with EC, 66 pts with surgery for NEEC were analyzed. Median age was 68.5 yrs (43-88). Serous histology was found in 34 (51.5%) pts, clear-cell in 13 (19.7%), in 18 (27.3%) carcinosarcoma and one pt had an undifferentiated tumor. Based on the International Federation of Gynecology and Obstetrics (FIGO) staging system, 32 pts (48.5%) were diagnosed at early stage (IA-II) and 34 (51,5%) at advanced stage (IIIA-IV). After surgery, 16 pts (24.4%) had no further treatment, while 11 (16.7%) received CT, 28 (42.4%) CT + RT and 11 (16.7%) only RT. RT included external beam RT and/or brachytherapy. In the survival analysis, the median DFS was significantly higher in the CT + RT group, 31 months (m), compared to both the RT alone group, 14m and the isolated CT group, 11m. For patients without further treatment DFS was 6m, p = 0.03. The median OS showed similar results: pts submitted to CT + RT had favorable survival (78m) compared to the other groups, RT group (64m), CT group (37m) and the group of pts with no further treatment (47m), p = 0.005.
Conclusions
The best survival results are for pts treated with CT+RT. Patients treated with RT had better results when compared with pts treated with CT or with pts without further treatment. These results show us that pts treated with CT are those with higher FIGO stages that were not considered for adjuvant RT. The worse survival results for untreated pts reflects deteriorated PS, extensive comorbidities or early progression. Due to aging and lifestyle risk factors, like obesity, EC remains the most prevalent gynecological carcinoma where better selection and implementation of adjuvant treatment modalities are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Author and co-authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract